Valtrex Related Published Studies
Well-designed clinical trials related to Valtrex (Valacyclovir)
Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. [2008.02]
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. [2008.01]
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. [2007.11.15]
Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study. [2007.10.01]
Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. [2007.09]
Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life. [2007.06]
A virologic pilot study of valacyclovir in infectious mononucleosis. [2007.05]
A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. [2007.05]
Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. [2007.01]
Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life. [2006.10.19]
Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. [2006.10]
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. [2006.09]
Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. [2006.07]
Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. [2006.07]
Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. [2006.03]
A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. [2005.09]
A randomized clinical trial of valacyclovir in multiple sclerosis. [2005.06]
Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. [2005.05]
Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. [2005.02.15]
Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. [2004.11.01]
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. [2004.11]
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. [2004.10.15]
The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures. [2004.09]
Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. [2004.07.22]
Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners. [2004.07]
No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. [2004.04]
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. [2004.01.01]
Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. [2003.10.01]
Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. [2003.07]
Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. [2003.03.15]
Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. [2003.03]
Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. [2003.03]
High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. [2003.03]
A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. [2002.12]
An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. [2002.10.15]
Valacyclovir in the treatment of facial herpes simplex virus infection. [2002.10.15]
Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. [2002.10]
Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. [2002.05]
Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. [2002.04.15]
Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. [2002.04.01]
Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. [2002.04]
Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. [2002.04]
Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. [2002]
Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. [2001.01]
Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. [2000.09]
Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. [2000.01]
A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. [1999.10]
Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. [1999.09]
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. [1999.05.13]
Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. [1998.10]
A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. [1998.02]
Effects of valacyclovir in cats infected with feline herpesvirus 1. [1997.10]
Well-designed clinical trials possibly related to Valtrex (Valacyclovir)
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial. [2008.10.17]
[Pharmacological treatment of Bell's palsy: favourable effects of prednisolone-based therapy now demonstrated] [2008.02.16]
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. [2007.02.22]
Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. [2006.11.28]
Bell's palsy: a review of treatment using antiviral agents. [2006.10]
The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. [2006.06]
A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. [2004.06]
Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. [2004]
Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. [2003.09]
Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial. [2003.01]
Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. [2002.12]
Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. [2002.06.15]
Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. [2002.02]
A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. [2002.01.08]
Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. [2002.01]
Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. [2002]
Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. [2001.06]
Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. [2001.06]
Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. [2000.11.27]
Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. [2000.08]
Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? [2000.03]
Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. [2000.01]
Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. [1999.12]
Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. [1998.09]
Advances in the treatment of herpesvirus infection: the role of famciclovir. [1998.07]
Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin. [1998.01]
The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. [1998.01]
A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. [1998.01]
Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. [1997.09]
Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. [1997.04]
Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. [1997.04]
Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. [1997.03]
A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. [1996.08.12]
Efficacy of famciclovir in the treatment of herpes zoster. [1996.06]
Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. [1996.01]
Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. [1995.12]
Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. [1995.07]
Estimating the value of a generic quality-of-life measure. [1995.04]
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. [1994.07]
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. [1993.12]
Other research related to Valtrex (Valacyclovir)
Valacyclovir for the treatment of Bell's palsy. [2008.10]
Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. [2008.10]
Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. [2008.09.01]
Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. [2008.09]
Pharmacokinetics of valacyclovir in the adult horse. [2008.08]
MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. [2008.08]
An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. [2008.07]
An International, Randomized, Double-Blind, Placebo-Controlled, Study of Valacyclovir for the Suppression of Herpes Simplex Virus Type 2 Genital Herpes in Newly Diagnosed Patients. [2008.05.05]
MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. [2008.05.05]
|
